NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Announces Supplying Blueprint Medicines’ Precision Therapy AYVAKIT™ (avapritinib)
Feb 27, 2020
Catalent welcomes the announcement by Blueprint Medicines Corporation that the FDA has approved AYVAKIT™ for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.
Perrigo and Catalent Announce FDA Approval of Perrigo’s AB-rated Generic Version of ProAir® HFA
Feb 25, 2020
Perrigo and Catalent today announced that the FDA has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA
Catalent’s Senior Vice President & Chief Financial Officer, Wetteny Joseph, Inducted as a Member of the Executive Leadership Council
Feb 24, 2020
Catalent today announced that Senior Vice President & Chief Financial Officer, Wetteny Joseph, has been inducted as a member of the Executive Leadership Council (ELC).
Catalent to Host Workshop Demonstrating Advantages of Integrated Biologics Development Solutions in London, U.K.
Feb 20, 2020
Catalent today announced it will host a one day workshop titled, “Achieving Integrated Biologics Development: Challenges and How to Tackle Them”.
Catalent Appoints Jim Walter as Vice President of Operations for Oral and Specialty Delivery
Feb 12, 2020
Catalent today announced the appointment of Jim Walter as Vice President of Operations for its Oral and Specialty Delivery business.
Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Feb 11, 2020
Catalent today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.
Catalent Completes Acquisition of MaSTherCell
Feb 10, 2020
Catalent, Inc. today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.
Catalent Recognized as a Country Certified Top Employer 2020
Feb 10, 2020
Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2020 in the United States.
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global
Feb 3, 2020
Catalent and MaSTherCell Global, Inc. today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of $315 million in cash.
Natural Product Expo West
Date: March 3-7, 2020
Setting Up Your Small Molecules and Biologics for Success
Date: March 5, 2020
Building Stronger Consulting Relationships to Advance Biologic Development Together
Date: March 11, 2020
CTS Europe
Date: March 11-12, 2020
Catalent & Evonik’s Hot Melt Extrusion Workshop
Date: March 12, 2020
Achieving Integrated Biologics Development
Date: March 12, 2020
Outsourcing Clinical Trials Israel 2020
Date: March 17-18, 2020
DCAT Week
Date: March 23-26, 2020
CTS New England
Date: March 24-25, 2020
BEBPA Bioassay Conference
Date: March 25-27, 2020
Master Class: How to Accelerate Early Drug Development in Oncology for Small Molecules and Biologics
Date: March 26, 2020
Drug Delivery Partnership
Date: March 30-April 1, 2020
In-Cosmetics Global
Date: March 31 – April 2, 2020
Rapid Developability Assessment of Early Phase Molecules: Parallel Screening of Enabling Technologies and Use of PBPK Modeling
Date: April 1, 2020
Building Stronger Consulting Relationships to Advance Biologic Development Together
Date: April 8, 2020
Drug Development Networking Summit
Date: April 16, 2020
CASSS BIOASSAY
Date: April 26-28, 2020
GCSG US Conference
Date: April 26-29, 2020